Mark G. Foletta

Mark G. Foletta joined the Board of Directors in June 2020. Most recently, Mr. Foletta was Executive Vice President and Chief Financial Officer of Tocagen, a clinical-stage biopharmaceutical company focused on advancing a cancer-selective gene therapy platform, prior to its merger with Forte Biosciences. Prior to Tocagen, Mr. Foletta was Chief Financial Officer of Biocept, Inc. and served as Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, Inc. He has held other management positions including Senior Vice President, Chief Financial Officer and Corporate Secretary of Intermark, Inc. and Triton Group Ltd. Earlier in his career Mr. Foletta worked at Ernst & Young, LLP. Mr. Foletta currently serves on the Boards of Directors of DexCom, Inc. and AMN Healthcare Services, Inc. He has previously served on the Boards of Directors of Regulus Therapeutics, Inc., Ambit Biosciences, Inc. and Anadys Pharmaceuticals, Inc. Mr. Foletta received a B.A. in Business Economics from the University of California, Santa Barbara and is a member of the Corporate Directors Forum.